Cargando…

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with cancer receiving chemotherapy, but its accuracy in identifying patients at high risk has been questioned. The aim of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muñoz, Andrés, Ay, Cihan, Grilz, Ella, López, Sonia, Font, Carme, Pachón, Vanesa, Castellón, Victoria, Martínez-Marín, Virginia, Salgado, Mercedes, Martínez, Eva, Calzas, Julia, Ortega, Laura, Rupérez, Ana, Salas, Eduardo, Pabinger, Ingrid, Soria, Jose Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414737/ https://www.ncbi.nlm.nih.gov/pubmed/36730884 http://dx.doi.org/10.1200/JCO.22.00255

Ejemplares similares

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
por: Muñoz Martín, Andrés J., et al.
Publicado: (2018)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2018)

Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020)

ABO blood group type and risk of venous thromboembolism in patients with cancer
por: Englisch, Cornelia, et al.
Publicado: (2022)

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study
por: Ay, Cihan, et al.
Publicado: (2022)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
por: Moik, Florian, et al.
Publicado: (2020)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer
por: Grilz, Ella, et al.
Publicado: (2019)

Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
por: Königsbrügge, Oliver, et al.
Publicado: (2016)

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
por: Bianconi, Daniela, et al.
Publicado: (2015)

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability
por: Ercan, Huriye, et al.
Publicado: (2021)

Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality
por: Riedl, Julia, et al.
Publicado: (2014)

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2020)

Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation
por: Hell, Lena, et al.
Publicado: (2021)

Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status
por: Rejtő, Judit, et al.
Publicado: (2023)

Prevention of venous thromboembolism in ambulatory patients with cancer
por: Khorana, Alok A, et al.
Publicado: (2020)

Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma
por: Mir Seyed Nazari, Pegah, et al.
Publicado: (2019)

Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence
por: Nopp, Stephan, et al.
Publicado: (2022)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options
por: Ay, Cihan, et al.
Publicado: (2017)

Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
por: García-Escobar, I., et al.
Publicado: (2020)

Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis
por: Hell, Lena, et al.
Publicado: (2020)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Plasma Clot Properties in Patients with Pancreatic Cancer
por: Thaler, Johannes, et al.
Publicado: (2023)

Acute venous thromboembolism in patients with brain cancer: clinical course
por: Becattini, Cecilia, et al.
Publicado: (2023)

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
por: Farge, Dominique, et al.
Publicado: (2022)

Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism
por: Jara-Palomares, Luis, et al.
Publicado: (2018)

Predictive Ability of a Clinical-Genetic Risk Score for Venous Thromboembolism in Northern and Southern European Populations
por: Salas, Eduardo, et al.
Publicado: (2021)

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020)

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
por: Ay, Cihan, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism
por: Ruiz-Artacho, Pedro, et al.
Publicado: (2018)

Pharmacological cancer treatment and venous thromboembolism risk
por: Muñoz Martín, Andrés J, et al.
Publicado: (2020)

Venous Thromboembolism In Cancer Patients: “From Evidence to Care”
por: Salgado, Mercedes, et al.
Publicado: (2022)

Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer
por: Moik, Florian, et al.
Publicado: (2020)

Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment
por: Soria, José Manuel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pg3o2p8abdl2c4cj9mmdcoe27q